Idogen AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDOGEN.ST research report →
Companywww.idogen.com
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.
- CEO
- Christina Herder
- IPO
- 2015
- Employees
- 6
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $12.79M
- P/E
- -0.16
- P/S
- 0.00
- P/B
- 2.09
- EV/EBITDA
- -0.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -652.21%
- ROIC
- -1328.13%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-47,608,000 · -22.52%
- EPS
- $-0.76 · 62.38%
- Op Income
- $-47,972,000
- FCF YoY
- -28.61%
Performance & Tape
- 52W High
- $0.12
- 52W Low
- $0.12
- 50D MA
- $0.12
- 200D MA
- $0.12
- Beta
- 1.78
- Avg Volume
- 0
Get TickerSpark's AI analysis on IDOGEN.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IDOGEN.ST Coverage
We haven't published any research on IDOGEN.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IDOGEN.ST Report →